ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) - ANVISA Registration 80254180310

Access comprehensive regulatory information for ANTI-CYCLIC CITRULLINATED PEPTIDE (ANTI-CCP) in Brazil's medical device market through Pure Global AI's free database. This Risk Class II medical device is registered under ANVISA number 80254180310 and manufactured by PHADIA AB. The registration is held by PHADIA DIAGNOSTICOS LTDA with validity until currently active (VIGENTE).

This page provides complete technical specifications for this device, regulatory compliance details, 5 similar products found using AI-powered semantic search, 5 companies making the same product including ABBOTT GMBH, BIO - RAD LABORATORIES INC., and 5 recent registrations in the same technical category. Pure Global AI offers free access to over 100,000+ Brazilian medical device registrations, helping global MedTech companies navigate ANVISA regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
100,000+ Devices
5 Similar Products
5 Competitors
80254180310
Registration Details
ANVISA Registration Number: 80254180310
Janaina dos Santos de Miranda

Janaina dos Santos de Miranda

🇧🇷 Brazil Regulatory Expert

Need help with your Brazil registration?

Contact Pure Global Brazil Team
Free consultation

Device Details

Registration Details

80254180310

25351265711201814

04930429000139

Company Information

PHADIA AB
Sweden
PT: SUÉCIA

Dates and Status

Aug 27, 2018

VIGENTE

09/18/2025 19:00:01